Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zinc pills could help seniors fight infections after hospital stay

NCT ID NCT07672132

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily 22 mg zinc supplement for 12 months can lower inflammation and reduce infections in adults aged 65 and older who were recently hospitalized. Researchers will measure blood markers, infection rates, hospital readmissions, and quality of life. 220 participants will be randomly assigned to receive zinc or a control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Zinc supplement (22 mg daily)
What this could lead to
If it works, this could point toward a simple, low-cost way to reduce inflammation and infections in older adults after hospitalization.
What could go wrong
This is a small, early-stage study with no phase designation. Zinc may not significantly affect inflammation or infection rates, and high doses can cause side effects like nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * above 65 years old included in ZOOM out ( clinical trials no: NCT07367412) * admittet at the medical emergency department Herlev Hospital Exclusion Criteria: * Patients receiving zinc supplements (\>10 mg daily) at time of inclusion * Patients with terminal illness (life expectancy \< 6 months, estimated by Clinical Frailty Scale ≥8) * Patients receiving parenteral nutrition (partial or complete) * Patients treated with hemodialysis or peritoneal dialysis * Patients known with severe dementia * Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Older medical patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.